

# Drugs@FDA: FDA Approved Drug Products

**f** SHARE ([HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021505](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=021505))

**t** TWEET ([HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA APPROVED DRUG PRODUCT S&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021505](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug Product S&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=021505))

**in** LINKEDIN ([HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021505&TITLE=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&SOURCE=FDA](https://www.linkedin.com/sharearticle?mini=true&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=021505&title=Drugs@FDA: FDA Approved Drug Products&source=fda))

**@** PIN IT ([HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON/?URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021505&DESCRIPTION=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS](https://www.pinterest.com/pin/create/button/?url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=021505&description=Drugs@FDA: FDA Approved Drug Products))



**✉** EMAIL ([MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021505](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=021505))



**PRINT**

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 021505

Company: UCB INC

**✉** EMAIL ([MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=021505](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&varapplno=021505))

- [Medication Guide](#)  
([https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/021035s100,021505s040lbl.pdf#page=28](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s100,021505s040lbl.pdf#page=28))
- [Other Important Information from FDA](#)  
(<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.htm>)

## Products on NDA 021505



CSV Excel Print

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code
KEPPRA	LEVETIRACETAM	100MG/ML	SOLUTION;ORAL	Prescription	AA

Showing 1 to 1 of 1 entries

## Approval Date(s) and History, Letters, Labels, Reviews for NDA 021505



## Labels for NDA 021505



**Therapeutic Equivalents for NDA 021505**